Interest in psilocybin as a treatment for depression, especially treatment-resistant depression, has grown, but phase 2 studies have been inconclusive. Issues like maintaining double-blinding and the role of adjunctive psychotherapy introduce biases that complicate clear results. Historical patterns with psychoactive substances show an initial excess of optimism followed by addictive behaviors and public health risks. The efficacy and safety of psilocybin treatment have not been unequivocally established. Excessive optimism among researchers may lead to widespread adoption without sufficient evidence. A cautious, measured approach is needed to balance innovation and prudence in advancing depression treatments.
Psilocybin combined with psychotherapy shows promise for treating depressive disorders, including major depressive disorder and treatment-resistant depression. Controlled and uncontrolled clinical trials report immediate and sustained antidepressant and anxiolytic effects, with benefits lasting up to 12 months post-treatment. Psilocybin has a favorable safety profile, is well-tolerated, and has low abuse potential. It may offer a valuable option for patients with depression, including those with comorbid terminal cancer. Future research is needed to confirm these findings and explore the synergistic interaction between psilocybin and psychological support.
A panel of 10 clinicians with experience treating major depressive disorder (MDD) used a modified Delphi process to develop 27 consensus recommendations for starting the medication dextromethorphan-bupropion extended release (45 mg/105 mg). The recommendations, which achieved a mean overall agreement score of 3.8, include using the drug as a first-line treatment for MDD, including when anxiety symptoms are present; individualizing treatment based on safety information in the Prescribing Information; using it for patients who had inadequate response, residual symptoms, or intolerable side effects from prior treatments; considering drug interactions when switching or adding medications; and switching cautiously from ketamine or esketamine due to their short-to-intermediate elimination half-lives. These recommendations offer practical guidance for initiating this treatment.